Editas Medicine
EDIT
193 hedge funds and large institutions have $90.9M invested in Editas Medicine in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 52 reducing their positions, and 26 closing their positions.
207% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $596K
78% more capital invested
Capital invested by funds: $51M → $90.9M (+$39.9M)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 194 → 193 (-1)
8% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 52
3.69% less ownership
Funds ownership: 53.03% → 49.34% (-3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.38M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$854K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$587K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$3.02M |
| 2 |
Morgan Stanley
New York
|
-$2.03M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$959K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$717K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$589K |
EDIT Hedge Fund Activity: Q2 2025 in Review
193 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2025, worth a combined $90.9M — up 78% from $51M a quarter earlier.
Fund positioning in EDIT was balanced in Q2 2025: 26 funds opened new positions, 26 closed out, 48 added to existing stakes and 52 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.6M. The largest seller was UBS AM, exiting entirely with an estimated $3.02M sold.
- 193 institutional investors held Editas Medicine (EDIT) as of Q2 2025, down from 194 in Q1 2025.
- Funds reported $90.9M of Editas Medicine stock for Q2 2025, up 78% quarter-over-quarter.
- 26 funds opened new Editas Medicine positions in Q2 2025 and 26 closed out, a net change of 0 holders.
- The largest Editas Medicine buyer in Q2 2025 was Millennium Management, an estimated $2.6M added.
- The largest Editas Medicine seller in Q2 2025 was UBS AM, an estimated $3.02M sold.
Based on aggregated 13F filings for Q2 2025.